Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Express Scripts
Cipla
Merck
Citi
Harvard Business School
McKesson
Chinese Patent Office

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,399,514

« Back to Dashboard

Which drugs does patent 8,399,514 protect, and when does it expire?

Patent 8,399,514 protects TECFIDERA and is included in one NDA.

This patent has sixteen patent family members in eleven countries.
Summary for Patent: 8,399,514
Title:Treatment for multiple sclerosis
Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
Inventor(s): Lukashev; Matvey E. (Tewksbury, MA), O'Neill; Gilmore (Medford, MA)
Assignee: Biogen Idec MA Inc. (Cambridge, MA)
Application Number:13/372,426
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,399,514
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,399,514

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING MULTIPLE SCLEROSIS ➤ Sign Up
Biogen Idec Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING MULTIPLE SCLEROSIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,399,514

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2137537 ➤ Sign Up C300674 Netherlands ➤ Sign Up
European Patent Office 2137537 ➤ Sign Up CA 2014 00035 Denmark ➤ Sign Up
European Patent Office 2137537 ➤ Sign Up PA2014024 Lithuania ➤ Sign Up
European Patent Office 2137537 ➤ Sign Up 1490038-5 Sweden ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Citi
Johnson and Johnson
Baxter
Chinese Patent Office
Medtronic
US Army
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.